Helping payers and providers close the mental health screening gaps, the company leverages its artificial intelligence-powered, voice-based vital sign to identify, measure and monitor the severity of depression and anxiety
WHO: Ellipsis Health, pioneer of the first voice-based vital sign to identify, measure and monitor the severity of depression and anxiety at scale, will showcase its powerful clinical support tool that fa cilitates behavioral health screening and longitudinal monitoring of symptoms and treatment efficacy at HLTH 2021. The event features senior leaders that will work together to help solve healthcare’s most pressing problems and discover the most promising opportunities to create health’s future.
WHAT: Coming off the heels of their $26 million in Series A funding announcement and being named the Champion of the 2021 Accenture Health Tech Innovation Challenge, Ellipsis Health will demonstrate how they are harnessing the unique power of voice to pioneer a new clinical standard in mental health care.
By using less than 60 seconds of the words people say (semantics) and how they say them (acoustics), the company's AI-powered clinical support tool can identify, measure and monitor depression and anxiety symptoms at scale. This much-needed solution helps providers and payers close the mental health screening and monitoring gaps, by quickly and reliably identifying at-risk individuals who need help sooner while providing visibility into people’s behavioral health over time and in-between care encounters.
Ellipsis Health’s Susan Solinsky, Co-Founder and Chief Growth Officer, will be available in-person at booth #5 in the UCSF Health Awards Innovation Pavilion to discuss the company’s mission to harness the unique power of voice to pioneer a new clinical standard in mental health care.
WHEN: October 17 – 21, 2021
WHERE: Boston, MA. Ellipsis Health Booth #5, UCSF Health Awards Innovation Pavilion.
About Ellipsis Health
Ellipsis Health has pioneered an artificial intelligence-powered, voice-based vital sign to measure and monitor depression, and anxiety severity at scale. With depression and anxiety symptoms impacting one-third of Americans and costing the global society over $1 trillion each year, Ellipsis Health’s integrated behavioral health solution helps healthcare payers and providers to reliably identify and stratify patient populations. Its solution assesses patient speech through cloud-based deep learning models to generate a real-time clinical score for the severity of anxiety and depression. To learn more about the HIPAA-compliant platform facilitating behavioral health screening and longitudinal monitoring of severity and treatment efficacy for depression and anxiety, please visit www.ellipsishealth.com or contact Susan Solinsky, Co-Founder, Chief Growth Officer and Chief Operating Officer, susan@ellipsishealth.com.
Comments